Objective: We summarized all published studies for endovascular stent graft placement among patients with type B aortic dissection in China with respect to clinical success, complications, and outcomes.
Abbreviation and Acronym
AD ¼ aortic dissection included; (3) a minimum series of 3 patients with type B AD treated with stent grafts was required for inclusion; and (4) case reports were not included. The selected articles were carefully reviewed, and data were extracted.
Data Extraction and Statistical Analysis
Each article was analyzed by using a standardized protocol according to the 53 predefined variables regarding clinical characteristics, procedural data, and in-hospital and long-term outcomes (see Table E1 ). Articles containing insufficient data (<25% of predefined variables) were excluded from the data extraction. Only articles including patients with type B AD subjected to endovascular stent graft placement were included, and articles with patients with other thoracic aortic pathologies (eg, thoracic aortic aneurysms) were discarded. Unspecified information was classified as not available. As a result, the number of patients (denominator) varies, with the specific variables reported in the analysis.
Rates of events were calculated as the number of events divided by the number of treated patients with available data. The approach to calculating individual rates for different studies and to combining these rates into a weighted average produces identical results if the weights are defined as the proportion of available patients provided in a specific study. Results are presented as mean AE standard error or median and range, where appropriate. No adjustment for multiple testing was applied because the statistical analysis was performed in an exploratory manner. Comparisons between patients in relation to publication date or in relation to operator's experience were made by using the 2-sided Student's t test for continuous variables. The life-table nonparametric method was used to generate estimates of survival at 30 days, 6 months, 1 year, 2 years, and 5 years. The Kaplan-Meier nonparametric method was used to generate estimates of 30-day mortality and 1-year survival in relation to publication date or in relation to operator's experience, and these values were compared by using the log-rank test. The 30-day procedure-related mortality of patients undergoing stent graft placement was compared with that of non-procedure-related mortality by using the log-rank test.
Definitions
AD was classified according to the Stanford classification. Dissection was considered an acute event if it occurred within the first 14 days from onset of symptoms, whereas it was considered chronic when occurring beyond 14 days. Complications were classified as major when life-threatening or prompting major therapeutic consequences (eg, access complications requiring surgical revision), whereas complications that did not require further treatment (eg, transient renal failure not requiring dialysis) were defined as minor. For the stent indication, Chinese vascular centers initially followed the indications for stent placement for type B dissection described by Nienaber and coworkers. 4 However, with accumulating experience, some experienced centers extended indications 1, 3, and 7. 4 Specifically, (1) when the distance from the entry site to the left subclavian artery is shorter than 1.5 cm, endovascular repair was still made after a left carotid-subclavian artery bypass [5] [6] [7] ; (2) endovascular repair was also performed, even when the maximal aortic diameter was less than 5.5 cm [5] [6] [7] ; and (3) when the bilateral iliac arteries were tortuous and stenosed, endovascular repair could be performed through the abdominal aorta. [5] [6] [7] The technical details of endovascular repairs were described by Nienaber and colleagues. 8 Procedural success was defined by the technically successful deployment of the endoprosthesis at the intended target location. Any death that occurred suddenly or could not be related to other causes was classified as being caused by aortic rupture. Reintervention was defined as the need for any surgical conversion or additional endovascular stent graft procedures. Procedure-related complications refer to complications that are related to endovascular stent placement (eg, retrograde dissection, organ or peripheral artery malperfusion, dissection rupture, type I endoleak, and stroke for subclavian artery occlusion). Non-procedure-related complications indicate complications that are not related to endovascular stent placement (eg, myocardial infarction, cancer, and multiple organ failure or stroke with no relation to stent graft treatment). Studies were analyzed according to the reported total number of patients treated with endovascular stent graft placement, including dissections and other diseases of the thoracic aorta (eg, thoracic aortic aneurysms), to evaluate the potential influence of the operator's experience on outcomes. Centers with a published total number of patients beyond the median (>16 patients) were considered more experienced than those with total numbers below the median. In addition, the results of stent graft placement were analyzed in relation to the study publication date. Specifically, studies pub- 
RESULTS

Study Selection
A total of 70 Chinese-language publications published between January 2001 and December 2007 met the inclusion criteria. Twenty-three of these articles were excluded because of potential duplicate publications, and 7 publications were excluded for insufficient data. One study that incorporated complementary data from another study was also excluded for data extraction. Thirty-nine studies were eventually selected for data extraction and analysis. A total of 1359 patients who underwent endovascular stent graft repair of the thoracic aorta were included in this analysis. Of these patients, 1304 (96.0%) had B-type AD (Table 1) . [5] [6] [7] 
Patient Characteristics
Seven hundred thirty-eight of 922 patients with available data had hypertension, and 130 of 696 patients with available data had cardiovascular risk factors, including 91 with coronary heart disease, 2 with aortic incompetence, and 37 with cardiac insufficiency (Table 2) . Of note, 23 of 1139 patients had evidence of aortic rupture, as shown with computed tomographic angiography, magnetic resonance angiography, or digital subtraction angiography. For the grafts used in these studies, 726 grafts from 656 available cases were indicated, including Talent (Medtronic, Inc, Minneapolis, Minn; n ¼ 341), Aegis (Microport, Inc, Shanghai, China; n ¼ 189), Vasoflow (Weike Medical Apparatus and Instrument, Inc, Suzhou, China; n ¼ 18), Endofit (Endomed, Inc, Phoenix, Ariz; n ¼ 15), Zenith (Cook, Inc, Bloomington, Ind; n ¼ 6), Powerlink (Endologix, Inc, Irvine, Calif; n ¼ 2), Aortec (YTH Biological Material Scitech, Inc, Beijing, China; n ¼ 55), Griking (Grikin Advanced Materials, Inc, Beijing, China; n ¼ 36), Ankura (Lifetech Scientific, Inc, Shenzhen, China; n ¼ 15), and homemade grafts (n ¼ 49).
Procedural Data and In-Hospital Course
The stent graft placement procedure was successful in 99.2% AE 0.1% of patients (Table 3 ). Emergency surgical conversion was required in 0.7% AE 0.1% of patients (Table , accounting for the total in-hospital conversion rate. Inhospital complications were reported in 4.4% AE 0.2% of patients (Table 3) . Complications were predominantly of major clinical significance (3.4% AE 0.1%), whereas minor complications were reported less frequently (1.0% AE 0.1%). The most critical in-hospital complications were related to retrograde extension of the dissection into the ascending aorta (0.4% AE 0.0%) and neurologic complications (0.6% AE 0.0%). Concerning neurologic complications, periprocedural stroke occurred in 0.2% AE 0.0% of patients, whereas no paraplegia was reported in 1284 patients. Thirty-four of 1304 patients with available data died during the in-hospital period (Table 3) , yielding an overall in-hospital mortality rate of 2.6% AE 0.1%. Within the 30-day period, there were no additional deaths, yielding a 30-day (operative) mortality rate of 2.6% AE 0.1%.
Follow-up Data
Patients were examined 1, 3, 6, 12, 24, and 60 months after discharge with computed tomographic scanning. The major parameters for the follow-up period have included false luminal thrombosis, morphous of stent, type I endoleak, and organ or peripheral arterial blood supply. Follow-up information was available for all 1304 patients ( Table 4) . The time to follow-up (27.1 AE 17.5 months) was available for only 1151 patients. False lumen thrombosis was reported in 92.9% AE 0.5% of the patients (Table 4) . Late surgical conversion was performed in 0.8% AE 0.1% of the patients, and adjunctive endovascular stent graft procedures were performed in 1.6% AE 0.1% of the patients. Therefore the total reintervention rate was 2.4% AE 0.1% over the follow-up period of 27.1 AE 17.5 months.
Aortic rupture occurred in 0.5% AE 0.0% of the patients during the follow-up period. A total of 1.5% AE 0.1% of the patients died during the follow-up period. Figure E1 shows survival rates for all patients in whom the exact time to death was available in life-table format. Specifically, the survival rates were 96.9% at 30 days, 96.7% at 6 months, 96.4% at 1 year, 95.6% at 2 years, and 95.2% at 5 years.
Results of Stent Graft Placement in Relation to Publication Date
Reported technical success rates were lower in the early studies published between 2001 and 2004 (94.7% AE 0.7%) when compared with the more recent studies published between 2005 and 2007 (99.6% AE 0.0%, P < .001, Table 5 ). The overall rate of complications was consistently higher in the earlier studies (11.4% AE 1.6% vs 3.8% AE 0.1%, P<.001). However, the rate of neurologic complications, in particular, was lower in comparison with that seen in the more recent studies (0% vs 0.7 AE 0.0%, P<.001). No significant difference was identified in operative or 1-year mortality between the 2 groups ( Table 5) .
Influence of Operator's Experience
As shown in Table 6 , centers with a total number of patients beyond the median had a better procedural success .2% AE 0.5% vs 2.5% AE 0.1% in 30-day mortality rate, P < .001). However, the rate of neurologic complications was higher in the centers with a total number of patients beyond the median (0.7% AE 0.0% vs 0%, P < .001, Table 6 ).
Procedure-Related Versus Non-Procedure-Related Mortalities Figure E2 depicts the procedure-related and non-procedure-related mortalities over the 30-day treatment period after the patients were accepted. Non-procedure-related mortality was higher than procedure-related mortality (1.8% AE 0.1% vs 0.8% AE 0.0%, P ¼ .016).
DISCUSSION
In this retrospective study we evaluated, by means of a large-scale meta-analysis, the efficacy of endovascular stent graft treatment for type B AD in China. Although the traditional antihypertensive therapy remains the first-line treatment for type B AD, endovascular stent graft placement is gaining more and more attention, especially with the high technical success rate and improved morbidity and mortality compared with those seen with its surgical counterpart. 8, 46 The concept of endovascular stent graft placement was propelled by the desire to induce aortic remodeling by means of exclusion of the false lumen and thrombosis of the false lumen and, at the same time, avoiding the risks associated with open surgical intervention. Clinical studies have suggested that patients with type B AD undergoing endovascular stent graft placement have a better midterm prognosis than those receiving antihypertensive medicine or undergoing traditional open surgical intervention. 47 For instance, Nienaber and colleagues 4 showed that in comparison with the traditional surgical treatment, stent grafting had a lower perioperative mortality (0% vs 8% for surgical treatment), lower mortality after 30 days (0% vs 8%), and lower mortality after 1 year (0% vs 33%) in patients with subacute or chronic type B AD. Similarly, the Investigation of Stent Grafts in Patients with Type B Aortic Dissection trial in Europe showed that treatment of uncomplicated AD by means of stent grafting plus antihypertensive medications has a 1-year survival rate of 95% in contrast to 77% for patients receiving antihypertensive treatment alone. 8 In addition, the European Collaborators on Stent Graft Techniques for Thoracic Aortic Aneurysm and Dissection (EUROSTAR) study showed that for 131 patients with AD (57% with complicated AD and 43% with uncomplicated AD) treated by means of endovascular stent grafting, the primary technical success was 89%, and paraplegia occurred in just 0.8% of patients. The outcome at 1 year was more favorable for stent treatment with regard to aortic expansion (0%) and late survival (90%). 48 Our study analyzed 1304 patients with type B dissection who underwent endovascular stent graft placement between 2001 and 2007 in China and demonstrated that endovascular stent graft treatment of AD was performed with a technical success rate of greater than 99%. Furthermore, our data 49 showed that stent grafting was associated with a 16% mortality within 30 days in patients with acute-type AD who had life-threatening complications. This figure for the same category of patients treated conventionally with an emergency surgical procedure is approximately 40% and as high as 70% for patients treated with drugs. [49] [50] [51] In addition, Hagan and colleagues 52 showed 31.4% and 10.7% of in-hospital mortalities for acute type B AD managed surgically and medically, respectively. Although our study and others support the idea that stent grafting is the optimal treatment for elective cases of type B AD in terms of acute and midterm survival rates, one should be extremely careful in drawing any conclusions without a randomized direct comparison with drug or surgical treatment strategies because patient selection might differ. Nevertheless, drug therapy is still the first-line treatment for type B AD, and stent grafting might have the potential to replace or supplement drug therapy.
In comparison with the study by Eggebrecht and colleagues, 2 our study of the Chinese-language literature suggests favorable rates of technical success, major complications, and improved acute and midterm survival. This might be because, first of all, the average age for patients with type B AD in our study is 10 years younger than that in the patients in the study by Eggebrecht and colleagues. In addition, some risk factors are much lower in our study than those in the study by Eggebrecht and colleagues. For example, the rate of acute dissection is 36.7% AE 1.0% in our study compared with 58.1% AE 1.8% in the study by Eggebrecht and colleagues. The rate of rupture dissection is 2.0% AE 0.2% in our study compared with 16.1% AE 1.2% in the study by Eggebrecht and colleagues. These risk factors have an effect on the patient's ability to tolerate the treatment and consequently have an effect on the outcome.
Second, the technique of stent grafting was applied in China 2 years after it was introduced to Europe and North America. This allowed the Chinese surgeons to have more time and chance to learn from their foreign counterparts, gaining both technical experience and the experience to assess the indications of the patients.
Third, our data reveal that this technique was being used in 4 major vascular surgery centers in China (Table 1) , with more than 145 cases in each center. The patients from these 4 centers account for 48.6% of all cases (634/1304), and the technical success rate is 99.5% (631/634). Because these 4 vascular surgery centers [5] [6] [7] 26 have a wealth of experience and that ensures that nearly half of the cases of type B dissection in our study have a high successful rate and a high early and midterm survival rate. In contrast, in the study by Eggebrecht and colleagues, 2 only a single center has an experience of more than 100 cases (20.9% [127/609]), and the other 79.1% of cases (582/609) were scattered over 38 vascular surgery centers, with the number of cases ranging from 3 to 38. Therefore we believe these contribute to the better success rate and the better rates of early and midterm survival in our study.
Neurologic complications, especially paraplegia, remain the most severe potential complications of stent graft placement, as for surgical repair of type B dissection. Occlusion of numerous critical intercostal arteries (Adamkiewicz artery) with stent grafts is widely believed to be responsible for the increased risk of paraplegia. 53 In particular, simultaneous abdominal and thoracic aortic repair with loss of lumbar and intercostal arteries appears to pose an increased risk of spinal cord damage because of insufficient collateral circulation. 54 Our analysis has shown that the overall risk of neurologic complications in patients treated with stent grafting was 0.6%, with none having paraplegia. In addition, our data demonstrated that stroke occurred in 0.2% of patients after stent graft treatment, which, again, is significantly lower than reported in the study by Eggebrecht and colleagues. 2 We believe that this is related to the age of the patients (52.1 years in our study vs 61.0 years in the report by Eggebrecht and colleagues) because younger patients might have a lower incidence of atherosclerosis and a relatively better circulation in the medium and small arteries. When the traffic artery or the left subclavian artery is occluded by stent grafting, other arteries can compensate for the blood supply for the spinal cord or brain, thereby reducing the incidence of paraplegia and stroke.
Although a favorable survival rate and a lower incidence of neurologic complications appear to be somewhat encouraging in these initial experiences, it should be noted that inhospital complications were encountered in 4.4% of patients and 40% of these complications were related directly to the procedure itself. Figure E2 shows a statistically significant difference between the mortality rate caused by a procedurerelated process and that caused by a non-procedure-related process during the 30-day postoperative period. However, it is interesting that we found this difference to be time related. As shown in Figure E2 , this difference was not apparent within 5 days after the procedure. The tendency of procedure-related mortality curve suggests that procedurerelated mortality most frequently occurs within 5 days of the operation, whereas the difference appeared 5 to 30 days after the operation. This could be useful information for the implication analysis after surgical intervention.
Our analysis suggests that centers with an experience of more than 16 stent graft procedures had a significantly higher success rate and a lower rate of complications than less experienced centers. Our data also suggested that the technical success rates have improved over time, which is accompanied by a decrease in 30-day mortality. However, neurologic complications have increased in the more recent studies compared with the earlier studies. This could be explained by the fact that the indications for stent graft placement have been expanded to include some high-risk patients who are more prone to complications while the experience in endovascular stent graft treatment grows. This was also evidenced by the fact that the spectrum of acute and midterm complications has broadened to include potentially disastrous events other than paraplegia or stroke. 55 Our meta-analysis highlights some other technical limitations of endovascular stent graft placement in patients with type B AD. Stent grafting failed to abolish the false lumen in 7% of patients, suggesting that it might not be a definitive treatment for type B AD. Even in the presence of a thrombosed thoracic false lumen, the distal thoracic or abdominal aorta might enlarge during follow-up. Therefore there is a continued risk for aortic rupture (about 0.5% during follow-up) after stent graft placement and a need for adjunctive stent graft placement or a need for open operations in 4% of patients over time. However, the incidence of aortic rupture and the need for repeat endovascular or surgical intervention might also be related to the progression of the disease itself and might not necessarily reflect treatment failure. This is supported by the fact that 11% to 20% and 10% to 44% of patients with type B AD require repeated operations when treated with drugs or treated surgically, respectively. 56, 57 Our analysis is the first to provide an overview of the literature on endovascular stent graft placement in patients with type B AD in China. Although it is not a prospective and randomized comparison with other treatment strategies for patients with type B AD, it provides an important insight into technical success, potential advantages and complications, and survival rates. However, several unavoidable limitations exist in this study.
First, the retrospective nature of this study might lead to potential bias in data collection, which would handicap the clinical applicability of the findings. Second, in general, it is impractical to include all hospitals in all regions in China. Although we were trying to be inclusive and systematic in our approach, we could only study patients who were admitted to these tertiary care centers. Third, there might be referral bias based on the type B AD of these medical centers. Finally, there might be some cases of type B AD that might have been overlooked. Nevertheless, we believe that our data truly represented valuable and reliable information related to stent placement for type B AD in China.
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FIGURE E1. The overall survival curve of patients undergoing stent graft placement. The survival rate was generated by using the life-table nonparametric method. The available number of patients was 1033 at 1 month, 719 at 20 months, 400 at 40 months, and 155 at 60 months. Specifically, the survival rates were 96.9% at 30 days, 96.7% at 6 months, 96.4% at 1 year, 95.6% at 2 years, and 95.2% at 5 years.
FIGURE E2. Thirty-day mortality of patients undergoing stent graft placement with procedure-related processes in comparison with those with nonprocedure related processes. The mortality data were generated by using the Kaplan-Meier method. Non-procedure-related mortality (triangles) was higher than procedure-related mortality (squares; 1.8% AE 0.1% vs 0.8% AE 0.0%, P ¼ .016) by using the log-rank test. 
